Get started
Author

Marti McKinley

Observed names: M. McKinley, Marti B. McKinley
OpenAlex ID: A5085023946
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
2005 · Sundar Jagannath, Brian G. M. Durie, et al. · British Journal of Haematology · 396
Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma
2009 · Sundar Jagannath, Brian G. M. Durie, et al. · British Journal of Haematology · 54
PDF
Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma.
2006 · Sundar Jagannath, Brian G.M. Durie, et al. · Blood · 38
Phase 2 study of two sequential three‐drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma
2009 · William I. Bensinger, Sundar Jagannath, et al. · British Journal of Haematology · 37
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
2012 · Jatin J. Shah, Edward A. Stadtmauer, et al. · Blood · 31
A Phase II Study of Bortezomib (Velcade ®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma
2008 · William Bensinger, Sundar Jagannath, et al. · Blood · 25
A Phase 2 Study of Bortezomib as First-Line Therapy in Patients with Multiple Myeloma.
2004 · Sundar Jagannath, Durie Brian, et al. · Blood · 23
Bortezomib Therapy Alone and in Combination with Dexamethasone for Patients with Previously Untreated Multiple Myeloma.
2005 · Sundar Jagannath, B. Durie, et al. · Blood · 20
A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study
2016 · Steven J. Cohen, Bert H. O’Neil, et al. · Cancer Chemotherapy and Pharmacology · 13
Second-line therapy of KRAS-mutated (KRASm) metastatic colorectal cancer (CRC) with the MEK inihibitor selumetinib ([SEL], AZ6244, ARRY-142886) in combination with irinotecan (IRI): An AGICC study.
2013 · Howard S. Hochster, Wells A. Messersmith, et al. · Journal of Clinical Oncology · 8
First-line therapy with bortezomib (formerly PS-341) in patients with multiple myeloma (MM)
2004 · S. Jagannath, B. Durie, et al. · Journal of Clinical Oncology · 7
A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma.
2007 · Sundar Jagannath, Bill Bensinger, et al. · Blood · 6
The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC).
2013 · Howard S. Hochster, Wells A. Messersmith, et al. · Journal of Clinical Oncology · 5
A phase IB study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: An Academic GI Cancer Consortium (AGICC) study.
2012 · Lawrence P. Leichman, Bert H. O'Neil, et al. · Journal of Clinical Oncology · 3
Phase I/II trial of bortezimib and pemetrexed in patients with advanced non-small cell lung cancer
2007 · R. B. Natale, M. McKinley, et al. · Journal of Clinical Oncology · 2
Effects of ZD6474, an orally active inhibitor of VEGF receptor tyrosine kinase, in patients with solid tumors: Results from a phase I study
2001 · S. Holden, S. Eckhardt, et al. · European Journal of Cancer · 2
Works count: 16
Citation count: 670
H-index: 9
I10-index: 9
Year
Topic
Type